The VanY<sub>D</sub> DD-carboxypeptidase of Enterococcus faecium BM4339 is a penicillin-binding protein

Peter E. Reynolds,¹ O. Herman Ambur,¹ Barbara Casadewall² and Patrice Courvalin²

Author for correspondence: Peter E. Reynolds. Tel.: +44 1223 333644. Fax.: +44 1223 333345. e-mail: per@mole.bio.cam.ac.uk

vanD-type Enterococcus faecium BM4339 is constitutively resistant to vancomycin and to low levels of teicoplanin. This strain produces peptidoglycan precursors terminating in D-lactate but, unlike VanA- and VanB-type strains, E. faecium BM4339 has a mutated ddl ligase gene and cannot synthesize D-Ala-D-Ala. Consequently, although it possesses vanX<sub>D</sub> and vanY<sub>D</sub> genes, it should not require an active VanX-type DD-dipeptidase or a VanY-type DD-carboxypeptidase for resistance. The vanY<sub>D</sub> gene contains the signatures of a penicillin-binding protein (PBP) and is believed to encode a penicillin-sensitive DD-carboxypeptidase. The enzyme activity was found to be membrane-bound and inhibited by low concentrations of benzylpenicillin in membrane preparations and in intact bacteria, indicating that the active site was present on the outside surface of the membrane. The 38 kDa protein was revealed as a PBP present in more copies per cell than conventional PBPs and all the protein was accessible to benzylpenicillin added externally, confirming the localization of the active site. A glycopeptide-susceptible strain of E. faecium lacked this PBP, and the membrane-bound DD-carboxypeptidase activity was less than 5% of that of E. faecium BM4339. Although the active site of VanY<sub>D</sub> was external to the membrane, UDP-MurNAc-tetrapeptide was produced internally, probably from UDP-MurNAc-pentadepsipeptide. The presence of benzylpenicillin at low concentrations in the growth medium substantially reduced the amount of tetrapeptide produced, indicating that inhibition of VanY<sub>D</sub> by benzylpenicillin influenced production of peptidoglycan precursors internally. A model to explain these contrasting observations is proposed.

Keywords: glycopeptide resistance, VanD phenotype, membrane-bound DD-peptidase, vancomycin resistance

INTRODUCTION

Glycopeptide antibiotics interfere with the last steps of peptidoglycan synthesis in Gram-positive bacteria (Nagarajan, 1991). These large molecules, which cannot penetrate the cytoplasmic membrane, form complexes with the C-terminal d-alanyl-d-alanine (d-Ala-d-Ala) of late peptidoglycan precursors when they are transported to the external side of the membrane (Reynolds, 1989). As a result, peptidoglycan precursors can no longer be incorporated into nascent peptidoglycan through the transglycosylation and the transpeptidation reactions. Release of the C-terminal d-Ala residue from pentapeptides, catalysed by penicillin-binding proteins (PBPs) displaying transpeptidase or DD-carboxypeptidase activity, is also inhibited (Arthur et al., 1996).

Enterococci with acquired VanA-, VanB- or VanD-type resistance to glycopeptides synthesize modified peptidoglycan precursors, ending in the depsipeptide d-alanyl-d-lactate (d-Ala-d-Lac) instead of the dipeptide d-Ala-d-Ala (Arthur et al., 1996). These modified precursors exhibit a 1000-fold reduced affinity for vancomycin (Bugg et al., 1991).

VanD-type resistance to glycopeptides in enterococci is
mediated by the chromosomal \textit{vanD} gene cluster, which includes at least six open reading frames (Casadewall & Courvalin, 1999; Périchon et al., 2000). The 5′ region of the \textit{vanD} operon contains the \textit{vanR}$_D$ and \textit{vanS}$_D$ genes encoding a two-component regulatory system. The \textit{vanY}$_D$ gene, located downstream, encodes a \textit{dB}-carboxypeptidase related to PBP5 (Casadewall & Courvalin, 1999). The 3′ part of the \textit{vanD} gene cluster includes the \textit{vanH}$_D$, \textit{vanD} and \textit{vanX}$_D$ genes, which encode a \textit{d}-Lac dehydrogenase, a \textit{dAAla:d}-Lac ligase and a \textit{dd}-dipeptidase, respectively. These proteins are homologous to the corresponding enzymes in VanA- and VanB-type strains.

VanD-type \textit{Enterococcus faecium} BM4339 is constitutively resistant to moderate levels of vancomycin (MIC 64 µg ml$^{-1}$) and to low levels of teicoplanin (MIC 4 µg ml$^{-1}$) (Périchon et al., 1997). In this strain, the \textit{vanD} gene cluster contains, at the 3′ end, the \textit{intD} gene, which encodes an integrase-like protein (Casadewall et al., 2001). The \textit{vanY}$_D$ gene is co-transcribed with \textit{vanH}$_D$, \textit{vanD}, \textit{vanX}$_D$ and \textit{intD} from the \textit{P}$_{id}$ promoter, whereas the \textit{vanR}$_D$ and \textit{vanS}$_D$ genes are expressed from the \textit{P}$_{pp}$ promoter (Casadewall et al., 2001). Due to a frameshift mutation in the chromosomal \textit{ddl} gene (Casadewall & Courvalin, 1999), \textit{E. faecium} BM4339 produces an impaired \textit{dAAla:dAAla} ligase (Ddl), accounting for the lack of \textit{dAAla:dAAla}-terminating peptidoglycan precursors in this strain (Périchon et al., 1997).

VanY$_D$ \textit{dd}-carboxypeptidase belongs to the PBP family of catalytic-serine enzymes which are susceptible to benzylpenicillin (Joris et al., 1988), whereas VanY$_A$ and VanY$_B$ from VanA- and VanB-type strains are penicillin-insensitive Zn$^{2+}$-dependent proteins (Arthur et al., 1998; Wright et al., 1992). In glycopeptide-resistant enterococci, both types of membrane-bound enzymes hydrolyse pentapeptide and/or pentadepsipeptide peptidoglycan precursors to tetrapeptides, but their catalytic efficiency depends on the substrate. Although some of the PBPs which function as \textit{dd}-carboxypeptidases preferentially cleave depsipeptide substrates (Rasmussen & Strominger, 1978), the Zn$^{2+}$-dependent VanY \textit{dd}-carboxypeptidase exhibits a higher catalytic efficiency for hydrolysis of substrates ending in \textit{dAAla:dAAla} (Arthur et al., 1998). VanY$_B$ has been shown to play a more important role in VanB-type resistance than VanY in VanA-type resistance (Reynolds, 1998). VanY$_B$ contributes to resistance by hydrolysing pentapeptide precursors rapidly after induction by vancomycin, whereas, in VanA-type strains, the high \textit{dAAla:dAAla} dipeptidase activity of VanX is sufficient for resistance (Arthur et al., 1994).

To characterize the VanY$_B$ PBP, we have studied the binding of benzyl[\textsuperscript{14}C]penicillin to VanY$_D$ in intact cells and in membrane preparations of \textit{E. faecium} BM4339. To determine the role of the VanY$_B$ \textit{dd}-carboxypeptidase activity in glycopeptide resistance in \textit{E. faecium} BM4339, we have investigated the effect of treatment of intact bacteria and membrane preparations with benzylpenicillin on enzymic activity. The results suggest an extracytoplasmic localization of the active site of VanY$_D$ and we propose a model to account for the presence of tetrapeptide in the cytoplasm of \textit{E. faecium} BM4339.

**METHODS**

**Strains and growth conditions.** Glycopeptide-resistant \textit{E. faecium} BM4339 (Périchon et al., 1997) and glycopeptide-susceptible \textit{E. faecium} ATCC 9790 were grown in brain heart infusion (BHI) broth or on BHII agar supplemented with yeast extract (0.5%, w/v) (BHY). Small culture volumes were incubated overnight at 37 °C. The cultures were diluted in BHY broth to an OD$_{660}$ less than 0.1 and incubated in an orbital incubator (100 r.p.m.) at 37 °C. Cultures were used in the exponential phase of growth (OD$_{660}$ 0.8–1.0). The MICs of antibiotics were determined using twofold dilutions of the antibiotics in BHY broth with an inoculum of 10$^8$ bacteria ml$^{-1}$. Tubes were incubated for 24 h at 37 °C.

**Analysis of precursors.** Extraction and analysis of soluble peptidoglycan precursors were carried out essentially as described previously (Arthur et al., 1998). Ramoplanin was used at a final concentration of 3 µg ml$^{-1}$ for 15 min to eliminate possible damage to the cytoplasmic membrane during accumulation of the precursors. After extraction with trichloroacetic acid and desalting on Sephadex G10, HPLC was used to separate the late peptidoglycan precursors and the relative amounts were determined from the integrated peak areas (Arthur et al., 1998).

**Preparation of membrane fragments.** A 20 ml culture at an OD$_{660}$ of 1.0 was centrifuged (25 000 g, 30 s), the pellet washed once in 50 mM Tris/HCl pH 7.2 and the cells resuspended in 0.9 ml of the same buffer. Then 100 µl lysosome (4 mg ml$^{-1}$) and 70 µl M1 muramidase (1 mg ml$^{-1}$) were added and the mixture incubated at 37 °C until osmotic lysis was complete as judged by clearing of the suspension and phase-contrast microscopy. DNase (25 µg ml$^{-1}$) and MgCl$_2$ (5 mM) were added and incubation continued for 3 min at 37 °C. The suspension was cooled to 4 °C and the membrane fraction collected by centrifugation at 48 000 g for 20 min. The pellet was washed in 50 mM Tris/HCl pH 7.2 and finally resuspended in the same buffer.

**Binding of benzyl[\textsuperscript{14}C]penicillin**

**Membrane labelling.** Ten microlitres of a membrane suspension (5 mg protein ml$^{-1}$) was incubated for 5 min at 37 °C with 2 µl of different concentrations of benzyl[\textsuperscript{14}C]penicillin (53 mCi mmol$^{-1}$; 1961 MBq mmol$^{-1}$). Then 2 µl unlabelled penicillin (3 mg ml$^{-1}$) was added and membrane proteins were solubilized by heating for 4 min at 98 °C after addition of Sample Buffer (New England Biolabs). The proteins were separated by SDS-PAGE on a 12% polyacrylamide gel using the Laemmli buffer system (Laemmli, 1970). The gel was stained with 0.1% Coomassie blue in 50% (v/v) methanol/10% (v/v) acetic acid for 30 min at 37 °C, destained with 10% (v/v) methanol/10% (v/v) acetic acid for 1 h at 37 °C and dried on 3 MM paper using a Hoeffer slab gel drier. PBPs were detected and the amounts of the 40–42 kDa penicilloyl–protein complex determined using a phosphorimager (Molecular Dynamics, model 425). Autoradiography on Kodak X-Omat film was carried out for 4 weeks to reveal minor PBPs.

**Intact cell labelling.** Bacteria were harvested, washed once in 50 mM Tris/HCl pH 7.2 and resuspended at 10 mg dry wt ml$^{-1}$. Aliquots of 50 µl were incubated with benzyl[\textsuperscript{14}C]penicillin for 5 min at 37 °C. The samples were diluted 10-fold in 50 mM Tris/HCl pH 7.2 containing...
unlabelled benzylpenicillin (2 mg ml\(^{-1}\)) and lysed by treatment with lysozyme (400 µg ml\(^{-1}\)) and M1 muramidase (70 µg ml\(^{-1}\)). Membranes were pelleted by centrifugation (48000 g, 20 min), washed once and resuspended in 10 µl 50 mM Tris/HCl pH 7-2. Membrane proteins were separated and PBPs determined as described above.

**Accessibility of dd-carboxypeptidase in intact bacteria.** Bacteria were harvested, washed once and resuspended at 2 mg dry wt ml\(^{-1}\) in 50 mM Tris/HCl pH 7-2. Aliquots (0.5 ml) were incubated with benzylpenicillin (1, 0.1 and 0.01 µg ml\(^{-1}\)) for 5 min at 37 °C, a large excess of β-lactamase (Neutrapen, Riker laboratories), 20000 units, was added and incubation continued for 1 min at 37 °C. The samples were diluted with 5 ml 50 mM Tris/HCl pH 7-2 at 4 °C and the bacteria harvested by centrifugation at 25000 g for 30 s. The pellet was resuspended in 5 ml of the same buffer and the centrifugation stage repeated. The bacterial pellet was resuspended in 0.5 ml Tris/HCl pH 7-2 containing lysozyme (200 µg) and M1 muramidase (35 µg) and incubated at 37 °C until lysis was complete (15 min). DNase (25 µg ml\(^{-1}\)) and 5 mM MgCl\(_2\) were added and incubation continued for 3 min. The membrane suspension was cooled to 4 °C and the membranes collected by centrifugation at 48000 g for 20 min. The pellets were resuspended in 250 µl 50 mM Tris/HCl pH 7-2 and dd-carboxypeptidase activity determined using 10 µl samples in duplicate.

**Assay of dd-carboxypeptidase activity**

**Determination of d-Ala released.** This was carried out essentially as described previously (Messer & Reynolds, 1992). A membrane preparation (10 µl, 0.8 mg protein ml\(^{-1}\)) was incubated in 50 mM Tris/HCl pH 7-2 with 10 mM pentapeptide for 30 min at 37 °C. d-Ala released from the substrate was determined using d-amino acid oxidase with o-dianisidine as the chromogen.

**Determination of UDP-MurNAc-tetrapeptide.** A membrane preparation (10 µl, 2 mg protein ml\(^{-1}\)) was incubated in 50 mM Tris/HCl pH 7-2 with 3.5 mM pentapeptide or pentadepsipeptide for 30 min at 37 °C. Proteins were removed by treatment with 5-sulphosalicylic acid, the supernatant diluted 35-fold to give a 100 µM solution of nucleotide precursors and the tetrapeptide product separated from the substrate by HPLC (Reynolds et al., 1999).

**RESULTS**

**Glycopeptide resistance and penicillin action**

*E. faecium* BM4339, in common with other *E. faecium* strains, was resistant to benzylpenicillin, with an MIC of 128 µg ml\(^{-1}\). It does not produce a β-lactamase, indicating that a PBP vital for peptidoglycan metabolism was not saturated at this antibiotic concentration. The MIC of vancomycin was 64 µg ml\(^{-1}\). However, the two antibiotics acted synergistically and no growth occurred when benzylpenicillin was present at 2 µg ml\(^{-1}\) and vancomycin at 8 µg ml\(^{-1}\). This observation implicated a penicillin-binding protein in the glycopeptide resistance mechanism of *E. faecium* BM4339. Synergism between penicillins and glycopeptides has already been observed in VanA-type enterococci and was accounted for by processing of d-Ala-d-Lac-ending precursors by a conventional PBP with high affinity for β-lactams (Gutmann et al., 1994).

**Effect of growth in the presence of benzylpenicillin on peptidoglycan precursors**

UDP-MurNAc-l-Ala-d-Glu-l-Lys-d-Ala (tetrapeptide) is present in the cytoplasm of *E. faecium* BM4339 after a 15 min incubation with ramoplanin, which inhibits the

---

**Table 1. Effect of benzylpenicillin on peptidoglycan precursors of *E. faecium* BM4339 and BM4458 (BM4339::pAT665(β,pdd))**

<table>
<thead>
<tr>
<th>Strain</th>
<th>Benzylpenicillin in growth medium (µg ml(^{-1}))</th>
<th>Peptidoglycan precursors (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Tetrapeptide</td>
</tr>
<tr>
<td>BM4339</td>
<td>0</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>BM4458</td>
<td>0</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>1</td>
</tr>
</tbody>
</table>
Fig. 2. The PBPs of E. faecium BM4339 and glycopeptide-susceptible E. faecium ATCC 9790. Membranes were incubated with benzyl[14C]penicillin, the membrane proteins separated and PBPs revealed as in the legend for Fig. 1. Lane M, protein standards; lane 1, Coomassie-stained membrane proteins of E. faecium BM4339; lane 2, PBPs of E. faecium BM4339; lane 3, PBPs of E. faecium ATCC 9790.

Transfer of GlcNAc from UDP-GlcNAc to C-55 undecaprenyl-P-P-MurNAc(pentapeptide) (lipid I) to produce lipid II (Somner & Reynolds, 1990). The β-carboxypeptidase activity believed to be catalysed by VanYp, is inhibited by benzylpenicillin (Périchon et al., 1997). If this enzyme is involved in the production of tetrapeptide in the cytoplasm, growth of E. faecium BM4339 in the presence of penicillin G followed by analysis of the precursors would be expected to result in a reduction of the amount of tetrapeptide produced. Low concentrations of benzylpenicillin in the growth medium caused the predicted reduction in tetrapeptide (Table 1). The effect of benzylpenicillin was more marked in E. faecium BM4458 [BM4339::pAT665(β-dld)]. This strain synthesizes pentapeptide and pentadepsipeptide precursors, but both the amount and percentage of pentapeptide increased substantially when benzylpenicillin (1 µg ml⁻¹) was included in the growth medium (Table 1), indicating that it was almost totally hydrolysed when VanYp was active.

Analysis of PBPs of E. faecium BM4339 and glycopeptide-susceptible E. faecium ATCC 9790

Incubation of a membrane preparation with various concentrations of benzyl[14C]penicillin indicated that E. faecium BM4339 contained a PBP which migrated as a doublet on SDS gels with an apparent molecular mass of 40–42 kDa. The protein was more heavily labelled than the normal complement of high- and low-M₁ PBPs involved in peptidoglycan metabolism and was saturated at low concentrations of benzylpenicillin (Fig. 1). The 40–42 kDa PBP was absent from membranes of E. faecium ATCC 9790 (Fig. 2). The protein was accessible to benzyl[14C]penicillin at low concentrations in intact bacteria and the 50% saturation level was similar to that obtained with binding to membrane preparations (Table 2). The penicilloyl–protein bond was stable but in a 4 h incubation at 37 °C the complex was degraded to a 32 kDa penicilloylpeptide that was no longer membrane bound, indicating that the membrane-spanning domain had been removed (result not shown). Previous growth of the bacteria in the presence of unlabelled benzylpenicillin (3 µg ml⁻¹) completely saturated the 40–42 kDa PBP, as rigorous washing of the bacteria followed by preparation of the membrane fraction and incubation with benzyl[14C]penicillin (10 µg ml⁻¹) resulted in less than 1% radioactivity bound to the protein relative to that in the control preparation obtained from bacteria grown in the absence of benzylpenicillin.

Table 2. Binding of benzyl[14C]penicillin to the 40–42 kDa protein doublet in membranes of E. faecium BM4339

<table>
<thead>
<tr>
<th>Benzyl[14C]penicillin (µg ml⁻¹)</th>
<th>Percentage bound</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Membrane preparation</td>
</tr>
<tr>
<td>30</td>
<td>[100]</td>
</tr>
<tr>
<td>10</td>
<td>94</td>
</tr>
<tr>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>1</td>
<td>99</td>
</tr>
<tr>
<td>0·3</td>
<td>44</td>
</tr>
<tr>
<td>0·1</td>
<td>14</td>
</tr>
<tr>
<td>0·03</td>
<td>2</td>
</tr>
</tbody>
</table>

Inhibition of β-carboxypeptidase activity by benzylpenicillin

The β-carboxypeptidase activity in membrane preparations of E. faecium BM4339 was inhibited by low concentrations of benzylpenicillin with an ID₅₀ of approximately 0·02 µg ml⁻¹ (Table 3). To investigate whether the activity was also inhibited by benzylpenicillin in intact bacteria, a washed suspension of E. faecium BM4339 was treated with different concentrations of the antibiotic followed by removal of unbound benzylpenicillin with β-lactamase and extensive washing prior to osmotic lysis of the bacteria and
UDP-MurNAc-pentadepsipeptide

Table 3. Inhibition of VanY<sub>D</sub> DD-carboxypeptidase of *E. faecium* BM4339 by benzylpenicillin

The values shown are the mean of two determinations with preparations from different cultures.

<table>
<thead>
<tr>
<th>Benzylpenicillin (µg ml&lt;sup&gt;-1&lt;/sup&gt;)</th>
<th>Inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Membrane preparation</td>
</tr>
<tr>
<td>0.0045</td>
<td>25</td>
</tr>
<tr>
<td>0.01</td>
<td>46</td>
</tr>
<tr>
<td>0.015</td>
<td>92</td>
</tr>
<tr>
<td>0.1</td>
<td>98</td>
</tr>
<tr>
<td>1.0</td>
<td>100</td>
</tr>
</tbody>
</table>

assay of DD-carboxypeptidase activity in the resultant membrane preparation. The activity was inhibited at concentrations of benzylpenicillin similar to those that completely inhibited the enzyme in membrane preparations (Table 3). A control to investigate the breakdown of the DD-carboxypeptidase–penicillin complex at 37 °C demonstrated that no activity was regained in the time taken to lyse the bacteria osmotically prior to recovery and washing of the membrane preparation. In a further control, membrane preparations from two glycopeptidase-susceptible strains of *E. faecium* were assayed for DD-carboxypeptidase activity at the same concentration of membrane protein: less than 5% of the DD-carboxypeptidase activity of membranes from *E. faecium* BM4339 was present, indicating that the normal low-M<sub>e</sub> PBPs of *E. faecium* BM4339 would not have contributed significantly to the release of d-Ala under the conditions of the experiment.

Substrate specificity of VanY<sub>D</sub> DD-carboxypeptidase

The substrate specificity of membrane-bound VanY<sub>D</sub> was investigated by following production of tetrapeptide from UDP-MurNAc-t-Ala-d-Glu-Lys-d-Ala-d-Ala (pentapeptide) or UDP-MurNAc-t-Ala-d-Glu-Lys-d-Ala-d-Lac (pentadepsipeptide) by HPLC. The activity of a membrane preparation of *E. faecium* BM4339 was more than threefold greater against pentapeptide than pentadepsipeptide and both activities were inhibited by benzylpenicillin (Table 4). The DD-carboxypeptidase activity of a membrane preparation of glycopeptide-susceptible *E. faecium* ATCC 9790 against pentapeptide was not detectable under the same conditions although low penicillin-susceptible activity was detected with pentadepsipeptide as substrate (Table 4).

DISCUSSION

Vancomycin resistance is expressed constitutively in *E. faecium* BM4339. A mutation in the *ddl* gene results in a defective d-Ala:d-Ala ligase and the consequent absence of peptidoglycan precursors ending in d-Ala-d-Ala. The constitutive phenotype could be due to a mutation in the *vanS<sub>D</sub>* gene (Casadewall & Courvalin, 1999) or to the activity of a different protein kinase able to upregulate expression of the *vanD* gene cluster (Casadewall et al., 2001). The majority of *E. faecium* isolates grow in high concentrations of benzylpenicillin because the vital target of penicillin is a PBP with low affinity. However, growth of *E. faecium* BM4339 in the presence of subinhibitory concentrations of benzylpenicillin resulted in a substantial decrease of the vancomycin MIC, indicating that a penicillin-sensitive reaction was likely to be involved in glycopeptide resistance of this strain. The percentages of peptidoglycan precursors in the cytoplasm were also altered as a result of growth of BM4339 or BM4458 [BM4339::pAT665(DD<sub>dl</sub>)] in the presence of benzylpenicillin, with a marked reduction in the amount of tetrapeptide present. This compound is produced as the result of DD-carboxypeptidase activity on pentapeptide or pentadepsipeptide precursors. These observations suggested that the active site of the penicillin-sensitive DD-carboxypeptidase was external to the cytoplasmic membrane because bacteria have been shown to be impermeable to benzylpenicillin (Cooper, 1956), but, in contrast, inhibition of its activity affected peptidoglycan precursors produced internally. The location of the active site of VanY<sub>D</sub>, the putative

Table 4. DD-Carboxypeptidase activity in *E. faecium* strains

Activities are expressed as nmol UDP-MurNAc-tetrapeptide produced min<sup>-1</sup> (mg membrane protein)<sup>-1</sup>. BPen, benzylpenicillin 100 µg ml<sup>-1</sup>.

<table>
<thead>
<tr>
<th>Strain</th>
<th>Substrate:</th>
<th>UDP-MurNAc-pentapeptide</th>
<th>UDP-MurNAc-pentadepsipeptide</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>−BPen +BPen % inhibition</td>
<td>−BPen +BPen % inhibition</td>
<td></td>
</tr>
<tr>
<td>BM4339</td>
<td>29.6 &lt; 0.01 100</td>
<td>8.6 0.4 96</td>
<td></td>
</tr>
<tr>
<td>ATCC 9790</td>
<td>0.01 &lt; 0.01 −</td>
<td>3.3 0.01 100</td>
<td></td>
</tr>
</tbody>
</table>
The dd-carboxypeptidase, was investigated by two methods: binding of benzyl[14C]penicillin to intact bacteria and membrane preparations, and secondly, measurement of enzyme activity in membrane preparations after treatment of membranes or intact bacteria with benzylpenicillin. The PBP profile of membrane proteins in VanD E. faecium BM4339, but not the amounts of individual PBPs, was virtually identical to that of the glycopeptide-susceptible E. faecium ATCC 9790, with the exception that a heavily labelled protein doublet was also present with a mass of 40–42 kDa, lower than that of any of the conventional PBPs of E. faecium isolates. The 40–42 kDa protein was saturated at a benzyl[14C]penicillin concentration of 1:0 µg ml−1 both in membrane preparations, where binding could have occurred from either or both sides of the membrane, and after binding to intact bacteria, in which benzylpenicillin should bind only to active sites exposed on the outside surface of the cytoplasmic membrane. The lack of binding of benzyl[14C]penicillin to the 40–42 kDa protein in membranes prepared from intact bacteria that had been grown in the presence of benzylpenicillin indicated that all the active sites of the protein were accessible to benzylpenicillin on the outside surface of the membrane. The amount of the 40–42 kDa PBP, as judged by the amount of bound radiolabel, was several-fold greater than the amount of any of the PBPs common to both glycopeptide-susceptible and -resistant strains, consistent with the probability that this PBP is VanY and possesses dd-carboxypeptidase activity. The calculated Mr of VanYD is 38,685, smaller than that obtained by comparison of the rate of migration in SDS gels with those of standard proteins, but such measurements can lead to anomalous values. There was a reasonable correspondence between the concentrations of benzylpenicillin that bound to the 40–42 kDa protein and those that inhibited dd-carboxypeptidase activity. Although the concentration of active benzylpenicillin in the radiolabelled preparation was assumed to be 100% of the value calculated on the basis of specific activity, freezing and thawing of the preparation over the course of several weeks would probably have resulted in some breakdown of the antibiotic, which would have affected the values given in Table 2. If breakdown had occurred, the correspondence between the two sets of data in Tables 2 and 3 may have been closer than those obtained. Furthermore the enzyme activity of membranes prepared from bacteria that had been pretreated with benzylpenicillin prior to lysis and collection of the membrane fragments for assay was inhibited at concentrations similar to those that inhibited the activity when membranes were exposed directly to benzylpenicillin, confirming that the active site was external to the cytoplasmic membrane. In strains expressing the VanA and VanB phenotypes it had previously been concluded that the presence of tetrapeptide peptidoglycan precursors in the cytoplasm resulted from the activity of membrane-bound VanY or VanYH, in which the active site was inside the cytoplasmic membrane, although the substrate was most likely to be a lipid intermediate carrying the peptidoglycan subunit (Arthur et al., 1998). The hydrophobicity profile of VanYD suggests that, in common with high-Mr PBPs, there is a single transmembrane segment close to the N-terminus. The penicillin-binding studies established that the tetrad motif SXXK containing the active-site serine is present external to the cytoplasmic membrane. This implies that the complete C-terminal domain of the protein that contains all the characteristic signatures of a PBP is present on the external face of the membrane.

Comparison of the dd-carboxypeptidase activities of membranes prepared from E. faecium BM4339 and from E. faecium ATCC 9790 provides strong evidence that the dd-carboxypeptidase activities measured in these investigations were catalysed by VanYD and not by another PBP. No dd-carboxypeptidase activity against pentapeptide was detected in the membranes of E. faecium ATCC 9790 by HPLC under the experimental conditions but a low level of activity against pentadepsipeptide was present, in agreement with the observations of Rasmussen & Strominger (1978) that PBPs may have greater activity against esters than peptides. Membranes containing VanYD possessed greater activity against pentapeptide than against pentadepsipeptide. Furthermore, a proportion of the activity against the latter substrate may have resulted from the activity of normal PBPs. In this respect, i.e. lower activity against esters than peptides, VanYD may differ from the classical PBPs though there is no obvious explanation for this difference. The fact that VanYD removes the terminal residue from both pentapeptide and pentadepsipeptide suggests that the tetrapeptide present in the cytoplasm following a short incubation with ramoplanin could have arisen from both precursors, though the amount of pentapeptide available as a substrate is likely to be small in view of the absence of an active d-Ala:d-Ala ligase. The small amount of pentapeptide present after growth of E. faecium BM4339 in the presence of benzylpenicillin could have resulted from the d-Ala:d-Ala ligase activity of VanD, which is assumed primarily to function as a d-Ala:d-Lac ligase (Casadewall & Courvalin, 1999). Studies with BM4458 [BM4339::pAT665(pddl)] confirmed that VanYD hydrolysed pentapeptide rapidly; the concentration of the precursor in the cytoplasm was reduced sixfold when the enzyme was active (Table 1).

It is difficult to explain how tetrapeptide, the product of the dd-carboxypeptidase reaction, is present inside the cell when the active site of the enzyme is on the outside surface of the cytoplasmic membrane. The peptidoglycan precursors were analysed after a 15 min incubation of the bacteria with ramoplanin (three times the MIC), which inhibits the conversion of lipid I to lipid II. As a result of the inhibition all the undecaprenyl lipid derivatives would be in the form of lipid I. The reaction in which P-MurNAcpentapeptide is added to undecaprenyl lipid-P is reversible and the position of equilibrium in a non-dynamic situation favours the reverse reaction in which the nucleotide peptidoglycan precursor would be re-formed. If lipid I containing MurNAcpentapeptide, when present in excess, could
Fig. 3. Model to demonstrate the normal incorporation of MurNAc-pentadepsipeptide into peptidoglycan (A) and to explain how the activity of VanYD with its active site on the outside surface of the membrane could catalyse the formation of UDP-MurNAc-tetrapeptide in the cytoplasm (B). Two key features of the model are the action of the enzyme UMP pyrophosphorylase, which catalyses the addition of P-MurNAc-pentapeptide to C-55 undecaprenyl-phosphate reversibly, and the assumption that lipid I (on the extreme right-hand side of the figure) can cross the membrane in both directions.

cross the membrane to the outside face (as does lipid II for peptidoglycan biosynthesis) it could be acted on by the VanYD DD-carboxypeptidase to generate lipid I containing a tetrapeptide; the results suggest that this may be able to re-cross the membrane to the cytoplasm, where it could be acted on by UMP pyrophosphorylase to produce the tetrapeptide derivative (Fig. 3).

The location of vanYD in the vancomycin-resistance operon presumably ensures high levels of vancomycin resistance in VanD strains that may not have a defective β-Ala:β-Ala ligase. Consequently it is unlikely to be involved in normal aspects of peptidoglycan metabolism, including control of the level of cross-linking and/or recycling of peptidoglycan degradation products. The location of the active site on the outside surface of the cytoplasmic membrane suggests that VanYD is probably involved in removing β-Ala from lipid intermediate II as it emerges through the membrane: this would ensure that vancomycin would not form a complex with lipid intermediate II and inhibit the membrane cycle of reactions of peptidoglycan synthesis. This cycle is particularly vulnerable as an antibiotic target, as the pool of C55-lipid carriers is only sufficient to maintain peptidoglycan synthesis for 10–15 s without continuous recycling of the lipid molecules. If this proves to be the role of VanYD, it raises the question as to the location of the active sites of VanY and VanYB, which have previously been assumed to be on the inside surface of the cytoplasmic membrane.

It is surprising that VanYD, with the motifs of a PBP and without the characteristic motifs present in the VanY and VanYB DD-carboxypeptidases or the VanXYC DD-peptidase/DD-carboxypeptidase, should nevertheless fulfil the same function. The gene is located in the vanD gene cluster in a comparable position to vanYB in the vanB cluster, namely downstream of the regulatory genes vanRD and vanSD and immediately upstream of vanW and the triplet of genes essential for vancomycin resistance [vanH, vanA(B,D), vanX]. This evolutionary diversity in arriving at the same solution in solving a problem highlights the ability of bacteria to adapt to potentially lethal situations in different ways.

ACKNOWLEDGEMENTS

B.C. is grateful to J. Blanchard for helpful discussions. This work was supported in part by a Bristol-Myers Squibb Unrestricted Biomedical Research Grant in Infectious Diseases, and by the Programme de Recherche Fondamentale en Microbiologie, Maladies Infectieuses et Parasitaires from the Ministère de l’Education Nationale, de la Recherche et de la Technologie. B.C. was the recipient of a Fellowship from the Fondation pour la Recherche Médicale. O.H.A. thanks Skipsreder Tom Wilhelmsens stiftelse for a grant.
REFERENCES


Received 15 December 2000; revised 4 June 2001; accepted 8 June 2001.